1
|
Assis MA, Carranza PG, Ambrosio E. A "Drug-Dependent" Immune System Can Compromise Protection against Infection: The Relationships between Psychostimulants and HIV. Viruses 2021; 13:v13050722. [PMID: 33919273 PMCID: PMC8143316 DOI: 10.3390/v13050722] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 04/14/2021] [Accepted: 04/19/2021] [Indexed: 01/31/2023] Open
Abstract
Psychostimulant use is a major comorbidity in people living with HIV, which was initially explained by them adopting risky behaviors that facilitate HIV transmission. However, the effects of drug use on the immune system might also influence this phenomenon. Psychostimulants act on peripheral immune cells even before they reach the central nervous system (CNS) and their effects on immunity are likely to influence HIV infection. Beyond their canonical activities, classic neurotransmitters and neuromodulators are expressed by peripheral immune cells (e.g., dopamine and enkephalins), which display immunomodulatory properties and could be influenced by psychostimulants. Immune receptors, like Toll-like receptors (TLRs) on microglia, are modulated by cocaine and amphetamine exposure. Since peripheral immunocytes also express TLRs, they may be similarly affected by psychostimulants. In this review, we will summarize how psychostimulants are currently thought to influence peripheral immunity, mainly focusing on catecholamines, enkephalins and TLR4, and shed light on how these drugs might affect HIV infection. We will try to shift from the classic CNS perspective and adopt a more holistic view, addressing the potential impact of psychostimulants on the peripheral immune system and how their systemic effects could influence HIV infection.
Collapse
Affiliation(s)
- María Amparo Assis
- Facultad de Ciencias Médicas, Universidad Nacional de Santiago del Estero (UNSE), Santiago del Estero G4200, Argentina;
- Laboratorio de Biología Molecular, Inmunología y Microbiología, Instituto Multidisciplinario de Salud, Tecnología y Desarrollo (IMSaTeD), CONICET-UNSE, Santiago del Estero G4206, Argentina
- Departamento de Psicobiología, Facultad de Psicología, Universidad Nacional de Educación a Distancia (UNED), 28040 Madrid, Spain;
- Correspondence:
| | - Pedro Gabriel Carranza
- Facultad de Ciencias Médicas, Universidad Nacional de Santiago del Estero (UNSE), Santiago del Estero G4200, Argentina;
- Laboratorio de Biología Molecular, Inmunología y Microbiología, Instituto Multidisciplinario de Salud, Tecnología y Desarrollo (IMSaTeD), CONICET-UNSE, Santiago del Estero G4206, Argentina
- Facultad de Agronomía y Agroindustrias, Universidad Nacional de Santiago del Estero, Santiago del Estero G4206, Argentina
| | - Emilio Ambrosio
- Departamento de Psicobiología, Facultad de Psicología, Universidad Nacional de Educación a Distancia (UNED), 28040 Madrid, Spain;
| |
Collapse
|
2
|
Silva RN, Oliveira LCG, Parise CB, Oliveira JR, Severino B, Corvino A, di Vaio P, Temussi PA, Caliendo G, Santagada V, Juliano L, Juliano MA. Activity of human kallikrein-related peptidase 6 (KLK6) on substrates containing sequences of basic amino acids. Is it a processing protease? BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS 2017; 1865:558-564. [PMID: 28254587 DOI: 10.1016/j.bbapap.2017.02.017] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Revised: 02/12/2017] [Accepted: 02/26/2017] [Indexed: 12/25/2022]
Abstract
Human kallikrein 6 (KLK6) is highly expressed in the central nervous system and with elevated level in demyelinating disease. KLK6 has a very restricted specificity for arginine (R) and hydrolyses myelin basic protein, protein activator receptors and human ionotropic glutamate receptor subunits. Here we report a previously unreported activity of KLK6 on peptides containing clusters of basic amino acids, as in synthetic fluorogenic peptidyl-Arg-7-amino-4-carbamoylmethylcoumarin (peptidyl-ACC) peptides and FRET peptides in the format of Abz-peptidyl-Q-EDDnp (where Abz=ortho-aminobenzoic acid and Q-EDDnp=glutaminyl-N-(2,4-dinitrophenyl) ethylenediamine), in which pairs or sequences of basic amino acids (R or K) were introduced. Surprisingly, KLK6 hydrolyzed the fluorogenic peptides Bz-A-R↓R-ACC and Z-R↓R-MCA between the two R groups, resulting in non-fluorescent products. FRET peptides containing furin processing sequences of human MMP-14, nerve growth factor (NGF), Neurotrophin-3 (NT-3) and Neurotrophin-4 (NT-4) were cleaved by KLK6 at the same position expected by furin. Finally, KLK6 cleaved FRET peptides derived from human proenkephalin after the KR, the more frequent basic residues flanking enkephalins in human proenkephalin sequence. This result suggests the ability of KLK6 to release enkephalin from proenkephalin precursors and resembles furin a canonical processing proteolytic enzyme. Molecular models of peptides were built into the KLK6 structure and the marked preference of the cut between the two R of the examined peptides was related to the extended conformation of the substrates.
Collapse
Affiliation(s)
- Roberta N Silva
- Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil
| | - Lilian C G Oliveira
- Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil
| | - Carolina B Parise
- Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil
| | - Juliana R Oliveira
- Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil
| | - Beatrice Severino
- Dipartimento di Farmacia, Università degli Studi di Napoli "Federico II", Via D. Montesano, 49, 80131 Napoli, Italy
| | - Angela Corvino
- Dipartimento di Farmacia, Università degli Studi di Napoli "Federico II", Via D. Montesano, 49, 80131 Napoli, Italy
| | - Paola di Vaio
- Dipartimento di Farmacia, Università degli Studi di Napoli "Federico II", Via D. Montesano, 49, 80131 Napoli, Italy
| | - Piero A Temussi
- The Wohl Institute, King's College London, 5 Cutcombe Rd, London SE5 9RT, UK; Dipartimento di Scienze Chimiche, Università di Napoli Federico II, Comp. Univ. Monte Sant'Angelo Via Cintia 21, 80126 Naples, Italy
| | - Giuseppe Caliendo
- Dipartimento di Farmacia, Università degli Studi di Napoli "Federico II", Via D. Montesano, 49, 80131 Napoli, Italy
| | - Vincenzo Santagada
- Dipartimento di Farmacia, Università degli Studi di Napoli "Federico II", Via D. Montesano, 49, 80131 Napoli, Italy
| | - Luiz Juliano
- Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil
| | - Maria A Juliano
- Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil.
| |
Collapse
|
3
|
Hayama T, Kamio N, Okabe T, Muromachi K, Matsushima K. Kallikrein Promotes Inflammation in Human Dental Pulp Cells Via Protease-Activated Receptor-1. J Cell Biochem 2016; 117:1522-8. [PMID: 26566265 DOI: 10.1002/jcb.25437] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Accepted: 11/10/2015] [Indexed: 12/29/2022]
Abstract
Plasma kallikrein (KLKB1), a serine protease, cleaves high-molecular weight kininogen to produce bradykinin, a potent vasodilator and pro-inflammatory peptide. In addition, KLKB1 activates plasminogen and other leukocyte and blood coagulation factors and processes pro-enkephalin, prorenin, and C3. KLKB1 has also been shown to cleave protease-activated receptors in vascular smooth muscle cells to regulate the expression of epidermal growth factor receptor. In this study, we investigated KLKB1-dependent inflammation and activation of protease-activated receptor-1 in human dental pulp cells. These cells responded to KLKB1 stimulation by increasing intracellular Ca(2+) , upregulating cyclooxygenase-2, and secreting prostaglandin E2 . Remarkably, SCH79797, an antagonist of protease-activated receptor-1, blocked these effects. Thus, these data indicate that KLKB1 induces inflammatory reactions in human dental tissues via protease-activated receptor 1. J. Cell. Biochem. 117: 1522-1528, 2016. © 2015 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Tomomi Hayama
- Department of Endodontics, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan
| | - Naoto Kamio
- Department of Endodontics, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan
| | - Tatsu Okabe
- Department of Endodontics, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan
| | - Koichiro Muromachi
- Department of Pulp Biology and Endodontics, Graduate School of Dentistry, Kanagawa Dental University, Yokosuka, Kanagawa, 238-8580, Japan
| | - Kiyoshi Matsushima
- Department of Endodontics, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan.,Research Institute of Oral Science, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba, 271-8587, Japan
| |
Collapse
|
4
|
Polymorphisms at the F12 and KLKB1 loci have significant trait association with activation of the renin-angiotensin system. BMC MEDICAL GENETICS 2016; 17:21. [PMID: 26969407 PMCID: PMC4788869 DOI: 10.1186/s12881-016-0283-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 03/01/2016] [Indexed: 12/30/2022]
Abstract
Background Plasma coagulation Factor XIIa (Hageman factor; encoded by F12) and kallikrein (KAL or Fletcher factor; encoded by KLKB1) are proteases of the kallikerin-kinin system involved in converting the inactive circulating prorenin to renin. Renin is a key enzyme in the formation of angiotensin II, which regulates blood pressure, fluid and electrolyte balance and is a biomarker for cardiovascular, metabolic and renal function. The renin-angiotensin system is implicated in extinction learning in posttraumatic stress disorder. Methods & Results Active plasma renin was measured from two independent cohorts- civilian twins and siblings, as well as U.S. Marines, for a total of 1,180 subjects. Genotyping these subjects revealed that the carriers of the minor alleles at the two loci- F12 and KLKB1 had a significant association with reduced levels of active plasma renin. Meta-analyses confirmed the association across cohorts. In vitro studies verified digestion of human recombinant pro-renin by kallikrein (KAL) to generate active renin. Subsequently, the active renin was able to digest the synthetic substrate angiotensinogen to angiotensin-I. Examination of mouse juxtaglomerular cell line and mouse kidney sections showed co-localization of KAL with renin. Expression of either REN or KLKB1 was regulated in cell line and rodent models of hypertension in response to oxidative stress, interleukin or arterial blood pressure changes. Conclusions The functional variants of KLKB1 (rs3733402) and F12 (rs1801020) disrupted the cascade of enzymatic events, resulting in diminished formation of active renin. Using genetic, cellular and molecular approaches we found that conversion of zymogen prorenin to renin was influenced by these polymorphisms. The study suggests that the variant version of protease factor XIIa due to the amino acid substitution had reduced ability to activate prekallikrein to KAL. As a result KAL has reduced efficacy in converting prorenin to renin and this step of the pathway leading to activation of renin affords a potential therapeutic target.
Collapse
|
5
|
Feener EP, Zhou Q, Fickweiler W. Role of plasma kallikrein in diabetes and metabolism. Thromb Haemost 2013; 110:434-41. [PMID: 23676986 DOI: 10.1160/th13-02-0179] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2013] [Accepted: 04/03/2013] [Indexed: 01/06/2023]
Abstract
Plasma kallikrein (PK) is a serine protease generated from plasma prekallikrein, an abundant circulating zymogen expressed by the Klkb1 gene. The physiological actions of PK have been primarily attributed to its production of bradykinin and activation of coagulation factor XII, which promotes inflammation and the intrinsic coagulation pathway. Recent genetic, molecular, and pharmacological studies of PK have provided further insight into its role in physiology and disease. Genetic analyses have revealed common Klkb1 variants that are association with blood metabolite levels, hypertension, and coagulation. Characterisation of animal models with Klkb1 deficiency and PK inhibition have demonstrated effects on inflammation, vascular function, blood pressure regulation, thrombosis, haemostasis, and metabolism. These reports have also identified a host of PK substrates and interactions, which suggest an expanded physiological role for this protease beyond the bradykinin system and coagulation. The review summarises the mechanisms that contribute to PK activation and its emerging role in diabetes and metabolism.
Collapse
Affiliation(s)
- E P Feener
- Edward P. Feener, PhD, Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215, USA, Tel.: +1 617 309 2599, Fax: +1 617 309 2637, E-mail:
| | | | | |
Collapse
|
6
|
Verweij N, Mahmud H, Leach IM, de Boer RA, Brouwers FP, Yu H, Asselbergs FW, Struck J, Bakker SJ, Gansevoort RT, Munroe PB, Hillege HL, van Veldhuisen DJ, van Gilst WH, Silljé HH, van der Harst P. Genome-Wide Association Study on Plasma Levels of Midregional-Proadrenomedullin and C-Terminal-Pro-Endothelin-1. Hypertension 2013; 61:602-8. [DOI: 10.1161/hypertensionaha.111.203117] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Niek Verweij
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Hasan Mahmud
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Irene Mateo Leach
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Rudolf A. de Boer
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Frank P. Brouwers
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Hongjuan Yu
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Folkert W. Asselbergs
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Joachim Struck
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Stephan J.L. Bakker
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Ron T. Gansevoort
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Patricia B. Munroe
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Hans L. Hillege
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Dirk J. van Veldhuisen
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Wiek H. van Gilst
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Herman H.W. Silljé
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| | - Pim van der Harst
- From the Department of Cardiology (N.V., H.M., I.M.L., R.A.d.B., F.P.B., H.Y., D.J.v.V., W.H.v.G., H.H.W.S., P.v.d.H.), Department of Internal Medicine (S.J.L.B., R.T.G.), Trial Coordination Center (H.L.H.), and Department of Genetics (P.v.d.H.), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands (F.W.A.); Department of Research and Development,
| |
Collapse
|
7
|
Abstract
The proprotein convertases (PCs) are secretory mammalian serine proteinases related to bacterial subtilisin-like enzymes. The family of PCs comprises nine members, PC1/3, PC2, furin, PC4, PC5/6, PACE4, PC7, SKI-1/S1P, and PCSK9 (Fig. 3.1). While the first seven PCs cleave after single or paired basic residues, the last two cleave at non-basic residues and the last one PCSK9 only cleaves one substrate, itself, for its activation. The targets and substrates of these convertases are very varied covering many aspects of cellular biology and communication. While it took more than 22 years to begin to identify the first member in 1989-1990, in less than 14 years they were all characterized. So where are we 20 years later in 2011? We have now reached a level of maturity needed to begin to unravel the mechanisms behind the complex physiological functions of these PCs both in health and disease states. We are still far away from comprehensively understanding the various ramifications of their roles and to identify their physiological substrates unequivocally. How do these enzymes function in vivo? Are there other partners to be identified that would modulate their activity and/or cellular localization? Would non-toxic inhibitors/silencers of some PCs provide alternative therapies to control some pathologies and improve human health? Are there human SNPs or mutations in these PCs that correlate with disease, and can these help define the finesses of their functions and/or cellular sorting? The more we know about a given field, the more questions will arise, until we are convinced that we have cornered the important angles. And yet the future may well reserve for us many surprises that may allow new leaps in our understanding of the fascinating biology of these phylogenetically ancient eukaryotic proteases (Fig. 3.2) implicated in health and disease, which traffic through the cells via multiple sorting pathways (Fig. 3.3).
Collapse
Affiliation(s)
- Nabil G Seidah
- Biochemical Neuroendocrinology Laboratory, Clinical Research Institute of Montreal, Montreal, QC, Canada H2W 1R7.
| |
Collapse
|
8
|
Abid K, Rochat B, Lassahn PG, Stöcklin R, Michalet S, Brakch N, Aubert JF, Vatansever B, Tella P, De Meester I, Grouzmann E. Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein. J Biol Chem 2009; 284:24715-24. [PMID: 19620246 DOI: 10.1074/jbc.m109.035253] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
There is little information on how neuropeptide Y (NPY) proteolysis by peptidases occurs in serum, in part because reliable techniques are lacking to distinguish different NPY immunoreactive forms and also because the factors affecting the expression of these enzymes have been poorly studied. In the present study, LC-MS/MS was used to identify and quantify NPY fragments resulting from peptidolytic cleavage of NPY(1-36) upon incubation with human serum. Kinetic studies indicated that NPY(1-36) is rapidly cleaved in serum into 3 main fragments with the following order of efficacy: NPY(3-36) >> NPY(3-35) > NPY(2-36). Trace amounts of additional NPY forms were identified by accurate mass spectrometry. Specific inhibitors of dipeptidyl peptidase IV, kallikrein, and aminopeptidase P prevented the production of NPY(3-36), NPY(3-35), and NPY(2-36), respectively. Plasma kallikrein at physiological concentrations converted NPY(3-36) into NPY(3-35). Receptor binding assays revealed that NPY(3-35) is unable to bind to NPY Y1, Y2, and Y5 receptors; thus NPY(3-35) may represent the major metabolic clearance product of the Y2/Y5 agonist, NPY(3-36).
Collapse
Affiliation(s)
- Karim Abid
- Division of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire Vaudois (CHUV), 1011 Lausanne, Switzerland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Nunes VA, Gozzo AJ, Sampaio MU, Juliano MA, Sampaio CAM, Araujo MS. Mapping of human plasma kallikrein active site by design of peptides based on modifications of a Kazal-type inhibitor reactive site. JOURNAL OF PROTEIN CHEMISTRY 2003; 22:533-41. [PMID: 14703987 DOI: 10.1023/b:jopc.0000005503.20628.4e] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Human plasma kallikrein (huPK) is a proteinase that participates in several biological processes. Although various inhibitors control its activity, members of the Kazal family have not been identified as huPK inhibitors. In order to map the enzyme active site, we synthesized peptides based on the reactive site (PRILSPV) of a natural Kazal-type inhibitor found in Cayman plasma, which is not an huPK inhibitor. As expected, the leader peptide (Abz-SAPRILSPVQ-EDDnp) was not cleaved by huPK. Modifications to the leader peptide at P'1, P'3 and P'4 positions were made according to the sequence of a phage display-generated recombinant Kazal inhibitor (PYTLKWV) that presented huPK-binding ability. Novel peptides were identified as substrates for huPK and related enzymes. Both porcine pancreatic and human plasma kallikreins cleaved peptides at Arg or Lys bonds, whereas human pancreatic kallikrein cleaved bonds involving Arg or a pair of hydrophobic amino acid residues. Peptide hydrolysis by pancreatic kallikrein was not significantly altered by amino acid replacements. The peptide Abz-SAPRILSWVQ-EDDnp was the best substrate and a competitive inhibitor for huPK, indicating that Trp residue at the P'4 position is important for enzyme action.
Collapse
Affiliation(s)
- V A Nunes
- Department of Biochemistry, Universidade Federal de São Paulo, Escola Paulista de Medicina, Rua Três de Maio, 100, 04044-020 São Paulo, SP, Brazil
| | | | | | | | | | | |
Collapse
|
10
|
Melo RL, Alves LC, Del Nery E, Juliano L, Juliano MA. Synthesis and Hydrolysis by Cysteine and Serine Proteases of Short Internally Quenched Fluorogenic Peptides. Anal Biochem 2001; 293:71-7. [PMID: 11373081 DOI: 10.1006/abio.2001.5115] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We developed sensitive substrates for cysteine proteases and specific substrates for serine proteases based on short internally quenched fluorescent peptides, Abz-F-R-X-EDDnp, where Abz (ortho-aminobenzoic acid) is the fluorescent donor, EDDnp [N-(ethylenediamine)-2,4-dinitrophenyl amide] is the fluorescent quencher, and X are natural amino acids. This series of peptides is compared to the commercially available Z-F-R-MCA, where Abz and X replace carbobenzoxy (Z) and methyl-7-aminocoumarin amide (MCA), respectively; and EDDnp can be considered a P(2)' residue. Whereas MCA is the fluorescent probe and cannot be modified, in the series Abz-F-R-X-EDDnp the amino acids X give the choice of matching the specificity of the S(1)' enzyme subsite, increasing the substrate specificity for a particular protease. All Abz-F-R-X-EDDnp synthesized peptides (for X = Phe, Leu, Ile, Ala, Pro, Gln, Ser, Lys, and Arg) were assayed with papain, human cathepsin L and B, trypsin, human plasma, and tissue kallikrein. Abz-F-R-L-EDDnp was the best substrate for papain and Abz-F-R-R-EDDnp or Abz-F-R-A-EDDnp was the more susceptible to cathepsin L. Abz-F-R-L-EDDnp was able to detect papain in the range of 1 to 15 pM. Human plasma kallikrein hydrolyzed Abz-F-R-R-EDDnp with significant efficiency (k(cat)/K(m) = 1833 mM(-1) s(-1)) and tissue kallikrein was very selective, hydrolyzing only the peptides Abz-F-R-A-EDDnp (k(cat)/K(m) = 2852 mM(-1) s(-1)) and Abz-F-R-S-EDDnp (k(cat)/K(m) = 4643 mM(-1) s(-1)). All Abz-F-R-X-EDDnp peptides were resistant to hydrolysis by thrombin and activated factor X.
Collapse
Affiliation(s)
- R L Melo
- Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio 100, 04044-020 São Paulo, Brazil
| | | | | | | | | |
Collapse
|
11
|
Goumon Y, Lugardon K, Gadroy P, Strub JM, Welters ID, Stefano GB, Aunis D, Metz-Boutigue MH. Processing of proenkephalin-A in bovine chromaffin cells. Identification of natural derived fragments by N-terminal sequencing and matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Biol Chem 2000; 275:38355-62. [PMID: 10988298 DOI: 10.1074/jbc.m007557200] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A large variety of proenkephalin-A-derived peptides (PEAPs) are present in bovine adrenal medulla secretory granules that are cosecreted with catecholamines upon stimulation of chromaffin cells. In the present paper, after reverse phase high performance liquid chromatography of intragranular soluble material, PEAPs were immunodetected with antisera raised against specific proenkephalin-A (PEA) sequences (PEA63-70 and PEA224-237) and analyzed by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. Thirty PEAPs were characterized in addition to enkephalins and whole PEA, indicating that preferential proteolytic attacks occurred at both N- and C-terminal regions. A similar approach was used to characterize PEA-derived fragments exocytotically released into the extracellular space that showed five additional minor PEAPs. Among all these naturally generated peptides, enkelytin, the antibacterial bisphos- phorylated C-terminal peptide (PEA209-237), was predominantly generated, as shown by MALDI-TOF mass spectrometry analysis, which constituted an efficient method for its identification. Finally, the data on PEA intragranular and extracellular processing in adrenal medulla are discussed in regard to the known enzymatic processing mechanisms. We note the high conservation of the cleavage points in evolutionarily diverse organisms, highlighting an important biological function for the released PEAPs.
Collapse
Affiliation(s)
- Y Goumon
- INSERM Unité 338, Biologie de la Communication Cellulaire, 67084 Strasbourg, France
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Rougeot C, Rosinski-Chupin I, Njamkepo E, Rougeon F. Selective processing of submandibular rat 1 protein at dibasic cleavage sites. Salivary and bloodstream secretion products. EUROPEAN JOURNAL OF BIOCHEMISTRY 1994; 219:765-73. [PMID: 8112327 DOI: 10.1111/j.1432-1033.1994.tb18556.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The amino acid sequence of submandibular rat 1 (SMR1) protein, deduced from its cDNA sequence, led to the prediction that the SMR1 gene encodes a hormone-like precursor [Rosinski-Chupin, I., Tronik, D. & Rougeon, F. (1988) Proc. Natl Acad. Sci. USA 85, 8553-8557]. SMR1 contains an N-terminal putative secretory signal sequence and a tetrapeptide (QHNP), located between dibasic amino acids which constitute the most common signal for prohormone processing. We have isolated and characterized from the male rat submandibular gland and its secretions three structurally related peptides, namely an undecapeptide (VRGPRRQHNPR), a hexapeptide (RQHNPR) and a pentapeptide (QHNPR) generated from SMR1 by selective proteolytic cleavages at pairs of arginine residues. The biosynthesis of these peptides is subjected to distinct regulatory pathways depending on the organ, sex and age of the rat. Furthermore, the peptides are differentially distributed in the submandibular gland and in resting or epinephrine-elicited submandibular salivary secretions, suggesting distinct proteolytic pathways for their maturation. The undecapeptide is generated in the gland of both male and female rats, but under basal conditions it is only released into the saliva in male animals. The hexapeptide is produced in large amounts in the gland of adult male rats and released into the saliva in both resting and stimulated conditions. The pentapeptide appears only in the male saliva and is present mostly under stimulated conditions. In addition, administration of epinephrine induces the release of the hexapeptide from the submandibular gland into the bloodstream. The evidence indicates that the rat submandibular gland can function as a dual exocrine and endocrine organ for the SMR1-derived hexapeptide, as has been reported for nerve growth factor, epidermal growth factor, renin and kallikrein. Although the biological activities of the SMR1-derived peptides are not yet known, their high production and adrenergic-induced release only into the saliva and bloodstream of adult male rats, suggest a physiological involvement in some male-specific processes.
Collapse
Affiliation(s)
- C Rougeot
- Département d'Immunologie, Institut Pasteur, Paris, France
| | | | | | | |
Collapse
|
13
|
Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D. Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. EUROPEAN JOURNAL OF BIOCHEMISTRY 1993; 217:247-57. [PMID: 8223562 DOI: 10.1111/j.1432-1033.1993.tb18240.x] [Citation(s) in RCA: 153] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Chromogranins are a family of acidic soluble proteins which exhibit widespread distribution in endocrine cells and neurons. Chromogranin A (CGA), the major soluble component of the secretory granules in chromaffin cells of the adrenal medulla, is a single polypeptide chain of 431 residues with an apparent molecular mass of 70-75 kDa and a pI of 4.5-5. In mature bovine chromaffin granules about 50% of the CGA has been processed. In the present paper, the structural features of the proteolytic degradation mechanism have been characterized with regard to the possible function of CGA as a prohormone, as suggested by recent studies. CGA-derived components present in chromaffin granules were subjected to either two-dimensional gel electrophoresis or HPLC and the N-terminal of each fragment was sequenced. Immunoblotting with antisera to specific sequences within the CGA molecule were used to characterize these fragments further at their C-terminal. In addition, a similar approach was performed to characterize CGA-derived fragments released into the extracellular space from directly depolarized bovine cultured chromaffin cells. Our results identified several proteolytic cleavage sites involved in CGA degradation. Intragranular processing occurs at 12 cleavage sites along the peptide chain located in both N- and C-terminal moieties of the protein; a preferential proteolytic attack in the C-terminal part was noted. We found that CGA processing also occurs in the extracellular space after release, generating new shorter fragments. The proteolytic cleavage sites identified in this study were compared with the cleavage points which are thought to be involved in generating CGA fragments with specific biological activity: pancreastatin, chromostatin and N-terminal vasostatin fragments. In addition, a new 12-amino-acid CGA-derived peptide corresponding to the sequence 65-76 was identified in the soluble core of purified chromaffin granules. This short peptide was released, together with catecholamines, after stimulation of cultured chromaffin cells suggesting its presence within the storage complex of chromaffin granules. The specific biological activity of this CGA-derived fragment remains to be determined.
Collapse
Affiliation(s)
- M H Metz-Boutigue
- Insitut National de la Santé et de la Recherche Médicale, Unité 338, Strasbourg, France
| | | | | | | |
Collapse
|
14
|
Swain MG, Vergalla J, Bergasa NV, Jones EA. Sympathetic nerves, but not the adrenal gland, contribute to elevated plasma levels of met-enkephalin in rats with acute cholestatic hepatitis. REGULATORY PEPTIDES 1993; 46:535-42. [PMID: 8210512 DOI: 10.1016/0167-0115(93)90254-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Met-enkephalin is known to circulate in human and animal plasma in low levels. However, the source(s) of plasma met-enkephalin have not been completely elucidated. It has been proposed that the adrenal gland, sympathetic nerves, pancreas and the gut might be implicated. Recently, markedly elevated levels of met-enkephalin have been documented in the presence of liver disease. To investigate potential sources of met-enkephalin in liver disease, rats with acute cholestatic hepatitis 24 h after gavage with alpha naphthylisothiocyanate (ANIT) 100 mg/kg were studied. Plasma met-enkephalin levels were determined by radioimmunoassay in plasma samples from normal, adrenalectomized, or chemically sympathectomized animals. In control rats, ANIT treatment resulted in a striking 8.7-fold increase in systemic venous met-enkephalin levels (inferior vena cava) (P < or = 0.0005) and a significant increase in peptidase-derived met-enkephalin levels (determined after trypsin/carboxypeptidase B digestion of plasma samples) (P < or = 0.05). ANIT-treatment also resulted in a 5.6-fold increase in portal vein met-enkephalin levels (P < or = 0.005). Portal vein met-enkephalin levels were only 1.2-fold higher than IVC levels in ANIT-treated rats (P < or = 0.05). Plasma activities of the two main enkephalin degrading enzymes, aminopeptidase and enkephalinase, were similar in control and ANIT-treated rats. Chemical sympathectomy, prior to ANIT treatment, decreased the elevation in inferior vena caval met-enkephalin levels by 35% (P < or = 0.005). Adrenalectomy did not alter ANIT-induced increases in circulating met-enkephalin levels (pNS).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- M G Swain
- Liver Diseases Section, NIDDK, National Institutes of Health, Bethesda, MD 20892
| | | | | | | |
Collapse
|
15
|
Parmer RJ, Miles LA, Xi XP, Gill BM, Wu HJ, O'Connor DT. Processing of chromaffin granule proteins: a profusion of proteases? Neurochem Int 1993; 22:361-7. [PMID: 8457772 DOI: 10.1016/0197-0186(93)90018-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Evidence suggests that proenkephalin and members of the chromogranin/secretogranin family of proteins are prohormone precursors, giving rise to a variety of peptides with biologic activity. However, the specific proteases responsible for cleaving these proteins in vivo have not been fully established. Several candidate proteases have been described, some of which have been shown to cleave these proteins in vitro. Proteolytic processing of the chromogranins may be particularly complex, occurring in specific tissue-dependent patterns. To account for this level of complexity several protease systems may be operative, either alone or in concert, both within the neurosecretory granule and in the extracellular space. Specific proteases which are available within neurosecretory cells or in the local extracellular environment, and which may cleave these prohormones include PC1 and PC2 (recently described members of the Kex2/furin family of endoproteases), as well as kallikrein, acetylcholinesterase, and, more recently, the plasminogen/plasmin protease system. The potential role of these specific proteases in the processing of proenkephalin and the chromogranins is discussed, in particular, in the context of possible processing clues available from recent analysis of cDNA and genomic intron/exon structure.
Collapse
Affiliation(s)
- R J Parmer
- Department of Medicine, University of California, San Diego 92161
| | | | | | | | | | | |
Collapse
|
16
|
Dillen L, Miserez B, Claeys M, Aunis D, De Potter W. Posttranslational processing of proenkephalins and chromogranins/secretogranins. Neurochem Int 1993; 22:315-52. [PMID: 8457770 DOI: 10.1016/0197-0186(93)90016-x] [Citation(s) in RCA: 62] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Posttranslational processing of peptide-precursors is nowadays believed to play an important role in the functioning of neurons and endocrine cells. Both proenkephalins and chromogranins/secretogranins are considered as precursor molecules in these tissues, resulting in posttranslationally formed degradation products with potential biological activities. Among the proteins and peptides of neuronal and endocrine secretory granules, the enkephalins and enkephalin-containing peptides have been most extensively studied. The characterization of the post-translationally formed degradation products of the proenkephalins have enabled the understanding of their processing pathway. Chromogranins/secretogranins represent a group of acidic glycoproteins, contained within hormone storage granules. The biochemistry, biogenesis and molecular properties of these proteins have already been studied for 25 years. The chromogranins/secretogranins have a widespread distribution throughout the neuroendocrine system, the adrenal medullary chromaffin granules being the major source of these storage components. Recent data provide evidence for a precursor role for all members of the chromogranins/secretogranins family although also several other functions have been proposed. In this review, some of the methods applied to study proteolytic processing are described. In addition, the posttranslational processing of chromogranins/secretogranins and proenkephalins, especially the biochemical aspects, will be discussed and compared. Recent exciting developments on the generation and identification of potential physiologically active fragments will be covered.
Collapse
Affiliation(s)
- L Dillen
- Department of Pharmaceutical Sciences, University of Antwerp, UIA, Belgium
| | | | | | | | | |
Collapse
|
17
|
Paik SR, Lewis RV. Purification and characterization of a putative proenkephalin cleaving enzyme. Arch Biochem Biophys 1992; 296:617-29. [PMID: 1632649 DOI: 10.1016/0003-9861(92)90618-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A putative proenkephalin-cleaving enzyme (PCE) extracted from bovine adrenal chromaffin granules was purified with soybean trypsin inhibitor high-performance affinity chromatography. The 12,600-fold purified enzyme was maximally active at pH 8.0. The enzyme was completely inhibited with lima bean trypsin inhibitor (0.1 mg/ml), soybean trypsin inhibitor (0.1 mg/ml), and p-(chloromercuri)benzenesulfonic acid (1.0 mM), indicating PCE is a serine protease with cysteine residues likely to be involved in its structure or activity. It exhibited significant autoproteolysis without specific substrates present. The substrate specificity and kinetic constants with the enkephalin-containing (EC) peptides Leu-9 and proenkephalin Peptides B, E, and F as substrates were studied. The cleavage patterns were substantially different than with trypsin digestion. PCE specifically recognized the paired basic amino acid residues and predominantly cleaved the peptide bonds between Lys and Arg sites and peptide bonds after Lys-Lys and Arg-Arg sites. Different Km and Vmax values for the different Lys-Arg sites indicate sequences in addition to the paired basic residues can affect enzyme activity. Also, the lower Km and Vmax of Peptide E suggest a higher affinity for this peptide but much slower cleavage. The C-terminally located Lys-Arg site appears responsible for this high affinity. Based on these observations, we propose the following: (a) the primary structure of these peptides contains enough information to be processed correctly by PCE and (b) PCE may be regulated by pH and Peptide E to prevent extensive processing of the intermediate EC peptides which are the major opioid peptides found in the adrenal chromaffin granules.
Collapse
Affiliation(s)
- S R Paik
- Department of Molecular Biology, University of Wyoming, Laramie 82071
| | | |
Collapse
|
18
|
Sawyer N, Rondeau N, Chrétien M, Seidah NG. Expression and sorting of rat plasma kallikrein in POMC-producing AtT-20 cells. DNA Cell Biol 1991; 10:259-69. [PMID: 1851425 DOI: 10.1089/dna.1991.10.259] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
A vaccinia virus (VV) vector was used to express rat plasma kallikrein (rPK) in the constitutively secreting cells, BSC-40, and in the endocrine regulated cells, AtT-20. Using a specific rPK antibody and a fluorogenic substrate, Phe-Phe-Arg-AMC, we demonstrated that in both cell lines VV infections resulted in the synthesis of an immunoreactive enzyme predominantly present as a zymogen which can be activated with trypsin. Stimulation of VV:rPK-infected AtT-20 cells with either 5mM 8-bromo-cAMP or 56 mM KCl resulted in a different pattern of rPK and ACTH secretion, strongly suggesting that rPK follows the constitutive secretory pathway. Finally, the 10% rPK activity found within AtT-20 cell extracts had no effect on pro-opiomelanocortin (POMC) processing either intracellularly or extracellularly. The above data show that the biosynthetic machinery of both cell lines analyzed does not allow the efficient activation of plasma prekallikrein. Finally, despite the PK's demonstrated ability to cleave various hormone precursors in vitro at pairs of basic residues, in vivo, we did not obtain evidence that this hepatic enzyme can also act as an intracellular pro-protein processing enzyme.
Collapse
Affiliation(s)
- N Sawyer
- J.A. DeSève Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Quebec, Canada
| | | | | | | |
Collapse
|
19
|
Seidah NG, Sawyer N, Hamelin J, Mion P, Beaubien G, Brachpapa L, Rochemont J, Mbikay M, Chrétien M. Mouse plasma kallikrein: cDNA structure, enzyme characterization, and comparison of protein and mRNA levels among species. DNA Cell Biol 1990; 9:737-48. [PMID: 2264928 DOI: 10.1089/dna.1990.9.737] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
There is differential regulation of liver mRNA levels of rat (r) and mouse (m) plasma kallikrein (PK), as observed on Northern blots. Affinity purification of mPK and rPK, microsequencing, and radioimmunoassay in either rat or mouse showed that the difference in mRNA levels does not appreciably affect the circulating PK concentration. Nuclear run-off assays demonstrated that the regulation of the mRNA level of PK is post-transcriptionally controlled. Complete cDNA sequence determination of mPK was achieved using a combination of polymerase chain reaction and lambda gt11 library screening procedures. Within the coding region, the overall sequence homology between mPK and rPK is about 91-92% in amino acid and nucleotide sequence. Although the 3' noncoding segment of mPK is shorter than that of rPK, we calculate a 53% homology with a 5% higher A/T content for mPK. The largest difference is found at the 5' end of the mRNAs: whereas rPK is predicted from its gene structure to have a 167-nucleotide leader sequence, mPK is expected to have more than 605 nucleotides, of which the last 291 are very similar to those found in the rPK gene. The regulation of the mRNA stability and/or turnover rate of PK may possibly be affected by its 5' end in a species-dependent manner.
Collapse
Affiliation(s)
- N G Seidah
- J.A. DeSève Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Basak A, Gong YT, Cromlish JA, Paquin JA, Jean F, Seidah NG, Lazure C, Chrétien M. Syntheses of argininal semicarbazone containing peptides and their applications in the affinity chromatography of serine proteinases. INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH 1990; 36:7-17. [PMID: 2401601 DOI: 10.1111/j.1399-3011.1990.tb00078.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Eight argininal semicarbazone containing peptides prepared by liquid phase synthesis were all found to be reversible inhibitors of model serine proteinases including trypsin and plasma kallikrein (PK). Among the peptides tested, those having a Lys residue at position P2 displayed the maximum binding potency towards PK. One of the peptides, Leu-enkephalin-argininal semicarbazone, a comparatively weak inhibitor, was chosen in order to develop an affinity-based purification protocol for PK. The affinity column was prepared by covalent attachment of the NH2-terminal moiety of the peptidyl semicarbazone to a solid-phase matrix bearing a spacer group. For efficient binding of PK, it was found necessary to optimize parameters like the concentration of inhibitor linked to the solid matrix, the ionic strength of the buffer used, the temperature and the pH. The majority of the bound enzyme could be recovered following elution with guanidine hydrochloride or benzamidine hydrochloride in a high salt buffer at pH 6.0. The usefulness of the affinity procedure towards the purification of other serine proteinases is also discussed.
Collapse
Affiliation(s)
- A Basak
- J.A. de Sève Laboratory of Molecular, Clinical Research Institute of Montreal, Quèbec, Canada
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Paquin J, Benjannet S, Sawyer N, Lazure C, Chrétien M, Seidah NG. Rat plasma kallikrein: purification, NH2-terminal sequencing and development of a specific radioimmunoassay. BIOCHIMICA ET BIOPHYSICA ACTA 1989; 999:103-10. [PMID: 2597701 DOI: 10.1016/0167-4838(89)90206-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Rat plasma kallikrein (rPK) was purified to homogeneity form plasma using affinity and high-performance liquid chromatography techniques, and subjected to NH2-terminal sequencing. The data showed that the sequenced segments of the regulatory (heavy) and catalytic (light) chains of the proteinase, respectively, display 73 and 91% sequence similarity with their counterpart in human plasma kallikrein. This sequence homology in conjunction with the determined molecular structure and inhibitor sensitivity support the identity of the isolated enzyme as plasma kallikrein. A polyclonal antiserum against rPK was obtained after immunization of rabbits with the purified enzyme, and a specific radioimmunoassay was developed. Since Tyr-iodinated rPK was not recognized by the antiserum, two alternative approaches were found to be successful. These included the use of a tracer consisting of rPK modified with either the affinity reagent 125I-labeled DTyr-Glu-Phe-Lys-Arg chloromethyl ketone or with the Bolton Hunter reagent. The usable range of the assay is between 15-150 fmol per tube. The antibody was shown to bind both monomeric and dimeric forms of rPK. Denaturation of the enzyme in sodium dodecyl sulfate does not abolish immune recognition only as long as the regulatory subunit is attached to the catalytic chain. Oxidation or reduction of rPK results in complete loss of immunoreactivity. This observation suggests that perhaps the disulfide linkage of the catalytic and regulatory polypeptides somehow helps to protect the antigenic epitope from denaturation. Alternatively, the epitope(s) recognized by the antibody spans a domain which includes both Tyr and Cys residues necessary for immune recognition.
Collapse
Affiliation(s)
- J Paquin
- J.A. de Sève Laboratory of Biochemical, Neuroendocrinology, Clinical Research Institute of Montreal, Quebec, Canada
| | | | | | | | | | | |
Collapse
|
22
|
Seidah NG, Ladenheim R, Mbikay M, Hamelin J, Lutfalla G, Rougeon F, Lazure C, Chrétien M. The cDNA structure of rat plasma kallikrein. DNA (MARY ANN LIEBERT, INC.) 1989; 8:563-74. [PMID: 2598771 DOI: 10.1089/dna.1989.8.563] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
From a liver cDNA library we have isolated and characterized the cDNA encoding rat plasma kallikrein. The cDNA structure contains 2,456 nucleotides with a 2,082-nucleotide-long open reading frame. Protein sequence data suggest that the signal peptide is 19 amino acids long. This results in a mature plasma prekallikrein containing 619 amino acids. Determination of tissue distributions using Northern blot analysis (3.0-kb transcript) and the polymerase chain-reaction methodology on RNA preparations demonstrated that in the rat the liver is the main source of this enzyme. Southern blots suggested the presence of a single gene coding for rat plasma kallikrein. Finally, although Southern blots revealed a homologous gene in mouse, the mRNA corresponding to the mouse hepatic proteinase is barely detectable on Northern blots, suggesting inefficient transcription or high turnover of the mRNA in this species.
Collapse
Affiliation(s)
- N G Seidah
- Laboratory of Biochemical Neuronendocrinology, Clinical Research Institute of Montreal, Quebec, Canada
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Shen FS, Roberts SF, Lindberg I. A putative processing enzyme for proenkephalin in bovine adrenal chromaffin granule membranes. J Biol Chem 1989. [DOI: 10.1016/s0021-9258(19)84873-1] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
24
|
Benore-Parsons M, Seidah NG, Wennogle LP. Substrate phosphorylation can inhibit proteolysis by trypsin-like enzymes. Arch Biochem Biophys 1989; 272:274-80. [PMID: 2751304 DOI: 10.1016/0003-9861(89)90220-8] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The effect of substrate phosphorylation on the susceptibility to proteolytic cleavage by trypsin-like enzymes was investigated using the model heptapeptide Leu-Arg-Arg-Ala-Ser-Leu-Gly, a peptide representing the endogenous phosphorylation site of pyruvate kinase. Phosphorylation of Ser 5 altered the kinetics of proteolysis by two proteases, trypsin and rat plasma kallikrein, both of which cleaved between Arg 3 and Ala 4. In the case of trypsin, phosphorylation decreased the rate of cleavage 47-fold. In the case of rat plasma kallikrein, phosphorylation decreased proteolysis 13-fold. Phosphorylation resulted in an apparent redirection of the preferential site from Arg 3 to Arg 2. Because sequences analogous to this model peptide are commonly found in exposed domains of globular proteins, and since these regions are susceptible to both phosphorylation and protease attack, the results indicate that substrate phosphorylation may selectively influence protein processing and turnover.
Collapse
Affiliation(s)
- M Benore-Parsons
- Research Department, Ciba-Geigy Corporation, Summit, New Jersey 07901
| | | | | |
Collapse
|